ArticleScientific reports2015
A combination approach to treating fungal infections.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 87 citations in OpenAlex.
- Article
- Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates.Scientific reports · 2025Article
- Knowledge and usage patterns of clotrimazole vaginal cream and tablet amongst females: a cross-sectional study.Frontiers in pharmacology · 2025Article
- Pluronic F-127 Enhances the Antifungal Activity of Fluconazole against ResistantACS infectious diseases · 2024Article
- The Combination of 3-Hydrazinoquinoxaline-2-Thiol with Thymoquinone Demonstrates Synergistic Activity Against DifferentInfection and drug resistance · 2024Article
- N-Butylphthalide Potentiates the Effect of Fluconazole Against Drug-ResistantInfection and drug resistance · 2024Article
- Latin American Plants against Microorganisms.Plants (Basel, Switzerland) · 2023Review
- Discovery and development of novel substituted monohydrazides as potent antifungal agents.RSC medicinal chemistry · 2023Article
- Review
- In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole againstJournal of fungi (Basel, Switzerland) · 2023Article
- Synergistic potential of teriflunomide with fluconazole against resistantFrontiers in cellular and infection microbiology · 2023Article
- Itraconazole-Loaded Ufasomes: Evaluation, Characterization, and Anti-Fungal Activity againstPharmaceutics · 2022Article
- Heterologous expression and biochemical characterisation of the recombinant β-carbonic anhydrase (MpaCA) from the warm-blooded vertebrate pathogenJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.Journal of fungi (Basel, Switzerland) · 2021Review
- Broad-Spectrum Antifungal Agents: Fluorinated Aryl- and Heteroaryl-Substituted Hydrazones.ChemMedChem · 2021Article
- Combining Genome-Wide Gene Expression Analysis (RNA-seq) and a Gene Editing Platform (CRISPR-Cas9) to Uncover the Selectively Pro-oxidant Activity of Aurone Compounds AgainstFrontiers in microbiology · 2021Article
- Styrylpyridinium Derivatives as New Potent Antifungal Drugs and Fluorescence Probes.Frontiers in microbiology · 2020Article
- Bismuth nanoparticles obtained by a facile synthesis method exhibit antimicrobial activity againstBMC biomedical engineering · 2020Article
- Structural design of microbicidal cationic oligomers and their synergistic interaction with azoles against Candida albicans.Scientific reports · 2019Article
- Synthesis and synergistic studies of isatin based mixed ligand complexes as potential antifungal therapeutic agents.Heliyon · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans. Their extensive use has led to the emergence of drug resistance, complicating antifungal therapy for yeast infections in critically ill patients. Combination therapy has become popular in clinical practice as a potential strategy to fight resistant fungal isolates. Recently, amphiphilic tobramycin analogues, C12 and C14, were shown to display antifungal activities. Herein, the antifungal synergy of C12 and C14 with four azoles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole (VOR), was examined against seven Candida albicans strains. All tested strains were synergistically inhibited by C12 when combined with azoles, with the exception of C. albicans 64124 and MYA-2876 by FLC and VOR. Likewise, when combined with POS and ITC, C14 exhibited synergistic growth inhibition of all C. albicans strains, except C. albicans MYA-2876 by ITC. The combinations of FLC-C14 and VOR-C14 showed synergistic antifungal effect against three C. albicans and four C. albicans strains, respectively. Finally, synergism between C12/C14 and POS were confirmed by time-kill and disk diffusion assays. These results suggest the possibility of combining C12 or C14 with azoles to treat invasive fungal infections at lower administration doses or with a higher efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.